AdvaMed Statement on CMS’s Proposed Rule for Breakthrough Technology Coverage

June 23, 2023

WASHINGTON, D.C. –  AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the recently issued proposed Transitional Coverage for Emerging Technologies (TCET) rule:

AdvaMed logo

“We’re pleased that CMS has finally issued the TCET notice.  While the draft rule requires further review, we are pleased that CMS recognizes the need to improve the coverage process for seniors. We continue to believe that immediate coverage of FDA approved technologies represents the best path forward to ensure seniors receive the benefits they need and America’s Medtech companies continue to lead the world in medical innovation.  We look forward to reviewing draft rule and working work with CMS and Congress to bring the certainty and transparency to medical innovation that American seniors deserve.”

During the rulemaking process,  AdvaMed wrote to CMS , outlining practical considerations the agency could easily incorporate into its proposed rule, reflecting feedback from the medical technology companies that are developing products and methods to diagnose and treat diseases, improve patient quality of life, and save lives.

From the letter :  “We believe that CMS, in order to advance its health equity and other goals, can and must play a critical role in advancing access to emerging innovations that would improve health outcomes for the array of Medicare beneficiaries it serves. We also believe that we share a common goal – the establishment of a clear and expeditious coverage process, based on scientifically sound clinical evidence with appropriate safeguards, for emerging technologies that will benefit Medicare-eligible patients.”

In March, the bipartisan Ensuring Patient Access to Critical Breakthrough Products Act was introduced in the House of Representatives by Reps. Brad Wenstrup (OH-02) and Suzan DelBene (WA-01). In response to the introduction of the bill, Whitaker said,  “Access to innovative, FDA-approved breakthrough technologies is vital for Medicare beneficiaries who are working with their doctors to treat illnesses and live healthy lives. This legislation is an important part of the ongoing reforms that are taking place within CMS to make this a reality for patients.” 


Improving patient access to breakthrough medical technologies is a top priority this year for AdvaMed, highlighted in the organization’s  Medical Innovation Agenda for the 118 th  Congress  earlier this year.  

February 20, 2026
Recognition highlights Brookhaven’s commitment to life sciences growth and biomanufacturing readiness Brookhaven, GA, Feb. 18, 2026 – The City of Brookhaven has been designated a BioReady Gold Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady Community program evaluates a community’s preparedness to support life sciences development across key areas, including zoning and permitting, utilities and infrastructure, workforce readiness, and coordination among local government and economic development partners. The Gold distinction represents a high level of readiness and alignment with industry needs. “Achieving Gold BioReady status underscores Brookhaven’s commitment to being a competitive destination for life sciences innovation and manufacturing,” said Aaron Szarowicz, City of Brookhaven Economic Development Director. “This designation reflects the intentional investments and partnerships we’ve built to support companies as they scale and create high-quality jobs in our community.” Brookhaven’s BioReady assessment highlighted the City’s modern infrastructure, strategic location within metro Atlanta, access to a skilled workforce, and collaborative approach between City leadership, regional partners, and the business community. Together, these assets position Brookhaven to support companies across the life sciences value chain—from research and development to scale-up and manufacturing. The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-zoned sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Brookhaven to compete more effectively for private investment and job creation. Georgia Life Sciences works to advance innovation, strengthen the workforce pipeline, and grow Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. For more information on the non-profit, membership-based organization, visit www.galifesciences.org . For more information about Brookhaven’s economic development initiatives, visit www.BrookhavenGA.gov/EconDev . ### Media Contact: Ann Marie Quill, Assistant Communications Director 404-205-3832 AnnMarie.Quill@BrookhavenGA.gov
February 18, 2026
Georgia Life Sciences Releases “Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector”
February 17, 2026
by Maria Saporta February 9, 2026
MORE POSTS